Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesaglitazar Dose-Finding Study in Type 2 Diabetes
NCT00280865Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2002
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of tesaglitazar in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by AstraZeneca. Primary endpoint: Fasting Plasma Glucose at 12 weeks. Started Apr 2002; status: completed.
02
Drugs
tesaglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00280865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00280865.